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Objective: Bilirubin is an antioxidant that may suppress lipid
oxidation. Elevated bilirubin is associated with decreased cardiovas-
cular events in HIV-uninfected populations. We examined these
associations in people living with HIV (PLWH).
Methods: Potential myocardial infarctions (MIs) and strokes were
centrally adjudicated. We examined MI types: type 1 MI (T1MI)
from atherosclerotic plaque instability and type 2 MI (T2MI) in the
setting of oxygen demand/supply mismatch such as sepsis. We used
multivariable Cox regression analyses to determine associations
between total bilirubin levels and outcomes adjusting for traditional
and HIV-specific risk factors. To minimize confounding by hep-
atobiliary disease, we conducted analyses limited to bilirubin values
,2.1 mg/dL; among those with fibrosis-4 values ,3.25; and among
everyone. We repeated analyses stratified by hepatitis C status and
time-updated atazanavir use.
Results: Among 25,816 PLWH, there were 392 T1MI and 356
T2MI during follow-up. Adjusted hazard ratios for the association of
higher bilirubin levels with T1MI were not significant. Higher
bilirubin levels were associated with T2MI. By contrast, among
PLWH on atazanavir, higher bilirubin levels were associated with
fewer T2MI (hazard ratio 0.56:0.33–1.00). Higher bilirubin levels
among those on atazanavir were associated with fewer T1MI
combined with ischemic stroke.
Limitations: Analyses were conducted with total rather than
unconjugated bilirubin.
Conclusions: Among PLWH, higher bilirubin levels were associ-
ated with T2MI among some subgroups. However, among those on
atazanavir, there was a protective association between bilirubin and
T2MI. These findings demonstrate different associations between
outcomes and elevated bilirubin due to diverse causes and the
importance of distinguishing MI types.
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INTRODUCTION
Bilirubin is the end product of heme catabolism and an
effective antioxidant that may suppress lipid oxidation.1–3
Bilirubin may also have anti-inflammatory, complement
inhibitory, and possibly antithrombotic and lipid-lowering
properties.4–6 Elevated bilirubin, particularly mildly elevated
levels,4 has been associated with fewer myocardial infarctions
(MIs) and strokes and with reduced carotid atherosclerosis, in
the general population and individuals with Gilbert
syndrome,2,3,7–11 although not always.12,13 The nature and
Received for publication April 15, 2018; accepted March 11, 2019.
From the aDepartment of Medicine, University of Washington, Seattle, WA;
bBristol Myers Squibb, Princeton, NJ; cDepartment of Medicine, University
of California Los Angeles, Los Angeles, CA; dDepartment of Medicine,
University of California San Diego, San Diego, CA; eDepartment of
Medicine, University of California San Francisco, San Francisco, CA;
fDepartment of Medicine, Johns Hopkins University, Baltimore, MD;
gDepartment of Medicine, University of North Carolina, Chapel Hill, NC;
hDepartment of Medicine, University of Alabama, Birmingham, AL; and
iDepartment of Epidemiology, University of Washington, Seattle, WA.
Supported by Bristol-Myers Squibb. Additional support came from the
National Institute of Allergy and Infectious Diseases (CNICS R24
AI067039, UW CFAR NIAID Grant P30 AI027757; UNC CFAR Grant
P30 AI50410, JHU CFAR Grant P30 AI094189, and UAB CFAR Grant
P30 AI027767), the National Institute of Drug Abuse (U01DA036935)
and the National Heart, Lung, and Blood Institute (R01HL126538) at the
National Institutes of Health, and from the American Heart Association
(13GRNT14560022). The following have received grant support or
served as consultants or advisors: P.W.H. with Merck and Gilead,
G.A.B. with DefiniCare, M.S.S. with BMS, Gilead, Merck, and ViiV,
R.D.M. with Medscape, J.J.E. with Merck, ViiV, BMS, Abbvie, Gilead,
and Tibotec/Janssen, D.R.D. with Gilead, H.M.C. with ViiV, and M.B.
has consulted for General Electric. The following are affiliated with BMS:
C.R. and L.R.
Presented in part at the 18th International Workshop on Comorbidities and
Adverse Drug Reactions in HIV; September 2016; New York, NY. 
The authors have no conflicts of interest to disclose.
Correspondence to: Heidi M. Crane, MD, MPH, University of Washington,
Seattle, WA 98104 (e-mail: hcrane@uw.edu).
magnitude of the relationship between bilirubin levels and 
atherosclerotic events is undefined.9,10
Relationships between bilirubin and atherosclerotic 
events are relevant to people living with HIV (PLWH), who 
have higher cardiovascular disease rates than the general 
population14–17 and may have abnormal bilirubin levels for 
several reasons. For example, the protease inhibitor atazana-
vir can cause hyperbilirubinemia due to inhibitor effects on 
UGT1A1 and has been a common component of HIV 
treatment regimens.18–20 A relationship has been reported 
between mild hyperbilirubinemia and slower progression of 
atherosclerosis in PLWH.21 It is unknown whether these 
associations translate into reduced risk of cardiovascular 
events such as MI with a recent study suggesting an 
association of higher bilirubin levels with lower cardiovas-
cular disease risk among PLWH.22 However, this association 
was not statistically significant for MI.
These relationships may differ by the type of cardio-
vascular events. The Universal Definition of MI classifies MI 
into types according to the underlying mechanism of 
myocardial ischemia,23,24 with type 1 MI (T1MI) and type 
2 MI (T2MI) being most common among PLWH. T1MI 
results spontaneously from atherosclerotic plaque instability. 
T2MI is related to oxygen demand–supply mismatch such as 
occurs with hypotension. Compared with the general pop-
ulation, where T2MIs comprise ,10% of MIs,25–30 we found 
that half of MIs among PLWH were T2MI31. T2MI among 
PLWH is due to causes such as sepsis and cocaine-induced 
vasospasm.31 Similarly, there are multiple types of strokes 
including ischemic and hemorrhagic with multiple subtypes 
of ischemic stroke,32 which are also associated with different 
predisposing causes and risk factors.
We conducted this study to examine relationships 
between bilirubin and cardiovascular events among PLWH, 
whether these associations differ by MI type or among 
atazanavir users, and to evaluate the hypothesis that higher 
bilirubin levels may protect against T1MI.
METHODS
Study Setting
A longitudinal observational study conducted in the 
Centers for AIDS Research Network of Integrated Clinical 
Systems (CNICS), a multisite clinical cohort of PLWH 
receiving HIV care.33
Study Participants
PLWH aged 18 years or older receiving HIV care at 6 
CNICS sites after adjudication of cardiovascular events began 
(dates varied by site, ;2000–2017). We started follow-up at 6 
months after enrollment and excluded individuals with events 
before the start of follow-up to ensure incident events.
Data Sources
The CNICS data repository integrates comprehensive 
clinical data from outpatient and inpatient encounters includ-
ing information on demographic characteristics, clinical and 
laboratory data, and medications. Laboratory data such as 
bilirubin values were collected as part of clinical care.
CNICS has an established state-of-the-art approach to 
cardiovascular outcome adjudication with MIs categorized by 
type.31,34 Potential MIs were identified in the centralized 
CNICS data repository using a comprehensive set of 
diagnostic and procedure codes and elevated cardiac bio-
marker values. For all potential events, sites assembled 
deidentified packets that included provider notes, electro-
cardiograms, and imaging results. Two physicians with 
expertise in cardiac disorders and adjudicating events re-
viewed each packet, followed by a third reviewer if discrep-
ancies occurred. Reviewers categorized MIs by type, 
identified causes for T2MI, and also identified PLWH without 
an MI but with coronary interventions such as a coronary 
artery bypass graft surgery, which were grouped with the 
T1MI. MI types beyond T1MI and T2MI are not discussed 
further because of low numbers (eg, there were ,10 type 4 
and 5 MIs associated with cardiac procedures in CNICS to 
date). We used a similar ascertainment and adjudication 
approach for strokes using provider notes, procedure reports, 
and imaging results in deidentified packets for centralized 
review. Reviewers categorized each stroke as ischemic vs. 
hemorrhagic. Ischemic strokes were further classified by 
whether concurrent infection or illicit drug use/intoxication 
was a predisposing factor when the stroke occurred.
Outcomes
We examined MIs by type. We also conducted 
sensitivity analyses with a combined atherosclerotic outcome 
(T1MI plus ischemic strokes excluding strokes related to 
infection or illicit drug use).
Analyses
Multivariable Cox regression analyses were used to 
determine associations between time-updated total bilirubin 
and outcomes, adjusting for traditional and HIV-specific risk 
factors: time-varying viral load (VL) and CD4 count, and 
baseline age, sex, race/ethnicity, HIV transmission risk factor, 
smoking status, hepatitis C virus (HCV) infection, diabetes, 
treated hypertension, statin use, kidney function (estimated 
glomerular filtration rate ,30, 30–60, $60), calendar time, 
and site. HCV status was based on positive laboratory values 
(antibody, genotype, or VL). Diabetes was based on any of 
the following: (1) hemoglobin A1c $ 6.5 OR (2) use of 
a diabetes-specific medication such as insulin OR (3) use of 
a diabetes-related medication not exclusively used to treat 
diabetes (eg, biguanides) in the setting of also having 
a diabetes diagnosis.35
Bilirubin values #30 days before outcomes were 
excluded to ensure outcomes or concurrent predisposing 
factors for T2MI such as sepsis were not impacting bilirubin 
values. To minimize confounding by hepatobiliary disease, 
we conducted analyses limited to bilirubin values ,2.1 mg/
dL as has been performed in the general population11 and 
repeated analyses limited to individuals who had fibrosis-4
(FIB-4) values ,3.25 at baseline. The FIB-4 index, derived
from age, liver aminotransferases, and platelet count, has been
shown to predict liver-related events and death.36–38 We also
conducted analyses where we examined everyone, regardless
of the bilirubin or FIB-4 level. We examined associations in
subgroups defined by HCV status. We examined the associ-
ations with total bilirubin as a continuous variable (log2
transformed), as a categorical variable (,0.6, 0.6–1.3, and
$1.3 mg/dL, with cut points selected based on the normal
adult range of up to 1.3 mg/dL), and using spline models to
examine the association of a 0.1 mg/dL change in bilirubin
within bilirubin categories.
We were particularly interested in any potential asso-
ciations with atazanavir both to add clarity as to mechanisms
and because of the potential clinical implications. We
conducted stratified analyses examining person-time on or
off atazanavir using time-updated models limited to those on
antiretroviral therapy (ART) and repeated these analyses
stratified by HCV status for those on non–atazanavir-con-
taining regimens. All bilirubin values obtained while on ART
were included. ART status varied over time based on whether
individuals were currently receiving ART prescriptions.
We conducted sensitivity analyses excluding those with
diabetes. We conducted sensitivity analyses stratified by sex.
In models stratified by sex, we adjusted for HCV but did not
stratify by HCV because of insufficient numbers among
subgroups of stratified analyses. We conducted sensitivity
analyses among the subset with indirect (unconjugated)
bilirubin values.
RESULTS
We included 25,816 PLWH. The mean age at baseline
was 40 years, 19% were female, 42% were white, and 18%
had HCV (Table 1). There was a median of 9 total bilirubin
values per person [interquartile range (IQR) 3–22]. The
median baseline total bilirubin was 0.6 mg/dL (IQR
0.4–0.8) among men and 0.5 mg/dL (IQR 0.3–0.6) among
women. During an average of 5.8 years of follow-up, 392
PLWH had a T1MI and 356 had a T2MI for an incidence rate
of 2.6 per 1000 person-years [95% confidence interval (95%
CI): 2.4 to 2.9] for T1MI and 2.4 per 1000 person-years (95%
CI: 2.2 to 2.7) for T2MI. Of the T2MI, 127 (36%) were
sepsis-related, 37 (10%) were related to cocaine-induced
vasospasm, and 192 (54%) were related to a variety of other
factors. There were 160 individuals with an ischemic stroke
not related to infection or illicit drug use. There were 476
PLWH who had a combined outcome of a T1MI or ischemic
stroke not associated with drug use or infection for an
incidence rate of 3.2 per 1000 person-years (95% CI: 2.9 to
3.5). Those with both an MI and stroke were categorized by
their first event.
Type 1 MI
In adjusted analyses, the hazard ratio (HR) for T1MI
was ,1.0 but not statistically significant (Table 2). For
example, in analyses including bilirubin levels ,2.1 mg/dL,
the HR for the association of higher bilirubin levels with
T1MI was 0.80 per 2-fold increase in bilirubin; 95% CI: 0.49
to 1.53 with similar findings among groups stratified by HCV
status. Findings were not statistically different than 1.0 in
analyses limited to those with baseline FIB-4 values ,3.25
and in analyses that included everyone. Similar results were
seen with categorical approaches (eg, bilirubin values
between 1.3 and 2.1 vs. ,0.6, HR 0.76; 95% CI: 0.33 to
1.72) and with spline models (data not shown). Similar
patterns of nonsignificant findings were found in sensitivity
analyses with an outcome of T1MI combined with ischemic
strokes not associated with drug use or infection (Table 2).
Type 2 MI
In adjusted analyses limited to bilirubin levels ,2.1
mg/dL, higher bilirubin levels were significantly associated
with T2MI overall (HR 1.70 per 2-fold bilirubin increase;
95% CI: 1.04 to 2.78) and in analyses stratified by HCV
status; higher bilirubin levels were significantly associated
with T2MI among those without HCV (HR 2.52 per 2-fold
bilirubin increase; 95% CI: 1.36 to 4.66) but not those with
HCV (HR 1.01; 95% CI: 0.45 to 2.30) (Table 2; interaction P
value, 0.01). Findings were similar in models limited to those
with baseline FIB-4 values ,3.25 but not in the models that
included everyone (Table 2) where there was no difference by
HCV status. In categorical analyses including bilirubin levels
,2.1 mg/dL, higher categories of bilirubin were associated
with T2MI, and this was driven by those without HCV.
Higher bilirubin levels (compared with bilirubin levels ,0.6)
were associated with T2MI (bilirubin levels 0.6–1.3: HR
1.61; 95% CI: 1.15 to 2.27; bilirubin levels 1.3–2.1: HR 2.70;
95% CI: 1.34 to 5.46) among those without HCV. In spline
models among everyone, a bilirubin increase of 0.1 in the
range of 0.6–1.3 was associated with an increased risk of
T2MI (1.09; 95% CI: 1.03 to 1.14), and this did not differ by
TABLE 1. Demographic and Clinical Characteristics Overall (N
= 25,816) and by Myocardial Infarction Status





N 25,816 25,068 392 356
Age (mean) 40 40 47 45
Female, % 19 19 14 29
Race, %
White 42 42 49 24
Black 40 40 38 65
Hispanic 13 13 10 8
Others/Missing 5 5 3 3
Hepatitis C, % 18 18 21 40
VL #400, % 61 61 61 51
CD4 cell count cells/mm3
(mean)
445 446 407 366
Bilirubin mg/dL (mean) 0.72 0.72 0.72 0.72
Percentages are the percent in each column with a particular characteristic. For
example, overall 19% of the included participants are women. However, among those
with a type 2 MI, 29% are women.
HCV status (without HCV, HR 1.09; 95% CI: 1.02 to 1.17;
with HCV, HR 1.10; 95% CI: 1.01 to 1.19).
Atazanavir and ART
In models limited to those on ART, we stratified by
atazanavir use (Table 3). During ART that did not include
atazanavir, the pattern of findings was similar to the overall
findings, showing a nonsignificant decreased risk of T1MI
(HR 0.70; 95% CI: 0.43 to 1.15) and a significantly increased
risk of T2MI associated with higher bilirubin levels (HR 2.00;
95% CI: 1.52 to 2.62). During ART that included atazanavir,
the association with T1MI was similar to the main analyses
with a HR ,1.0 but not statistically significant. Higher
bilirubin levels were associated with significantly fewer of the
combined outcome of T1MI and ischemic stroke (HR 0.64;
0.41 to 0.99). However, the association with T2MI was
different than among those not on atazanavir: higher bilirubin
levels were associated with significantly fewer T2MI events
(HR 0.56; 95% CI: 0.33 to 1.00).
Sensitivity Analyses
For the analysis shown in Table 2, findings did not
differ in analyses that excluded those with diabetes. In
adjusted analyses adjusting for HCV status and stratified by
sex limiting to those with bilirubin values ,2.1, associations
with T1MI were not significant, whereas for T2MI, higher
TABLE 2. Associations of Bilirubin Levels With Cardiovascular Outcomes Limited to Bilirubin Values,2.1 mg/dL, Limited to Those
With FIB-4 Values ,3.25, and Among Everyone Stratified by Hepatitis C Virus Coinfection Status in Adjusted Analyses*
Outcome
Hazard Ratio Per 2-Fold Increase in Bilirubin (95% CI)
HCV-Uninfected and Infected (Combined)
Stratified by HCV Status
HCV-Uninfected HCV-Infected
N (limited to bilirubin values ,2.1 mg/dL) 20,604 17,127 3477
Type 1 MI 0.80 (0.49 to 1.33) 0.78 (0.45 to 1.37) 0.88 (0.29 to 2.72)
Type 2 MI 1.70 (1.04 to 2.78) 2.52 (1.36 to 4.66) 1.01 (0.45 to 2.30)
Type I MI and ischemic stroke 0.87 (0.56 to 1.34) 0.98 (0.60 to 1.58) 0.53 (0.19 to 1.47)
N (limited to those with FIB-4 values ,3.25 at baseline) 24,205 20,190 4015
Type 1 MI 1.01 (0.80 to 1.28) 1.04 (0.80 to 1.35) 0.90 (0.50 to 1.61)
Type 2 MI 1.35 (1.07 to 1.72) 1.56 (1.19 to 2.06) 1.00 (0.63 to 1.60)
Type I MI and ischemic stroke 0.99 (0.79 to 1.23) 0.99 (0.78 to 1.26) 0.97 (0.59 to 1.60)
N (all) 25,816 21,111 4705
Type 1 MI 0.98 (0.78 to 1.23) 0.99 (0.77 to 1.29) 0.93 (0.56 to 1.56)
Type 2 MI 1.47 (1.19 to 1.82) 1.53 (1.17 to 2.00) 1.42 (1.02 to 1.98)
Type I MI and ischemic stroke 0.98 (0.79 to 1.20) 0.94 (0.74 to 1.20) 1.06 (0.70 to 1.61)
*Analyses adjusted for time-varying viral load and CD4 count, and baseline age, sex, race/ethnicity, HIV transmission risk factor, smoking status, HCV status, diabetes, treated
hypertension, statin use, kidney function (estimated GFR ,30, 30–60, $60), calendar time, and site. Analyses stratified by HCV not adjusted for HCV.
FIB-4, fibrosis-4 index; GFR, glomerular filtration rate; MI, myocardial infarction.
TABLE 3. Associations of Bilirubin Levels With Cardiovascular Outcomes Among Those on Antiretroviral Therapy Stratified by
Atazanavir Use and by Hepatitis C Virus Coinfection Status in Adjusted Analyses*,†
Outcome
Hazard Ratio Per 2-Fold Increase in Bilirubin (95% CI)
HCV-Uninfected and Infected (Combined)
Stratified by HCV Status
HCV-Uninfected HCV-Infected
N (limited to those on ART not including atazanavir) 20,305 16,706 3599
Type 1 MI 0.70 (0.43 to 1.15) 0.65 (0.36 to 1.17) 0.82 (0.33 to 2.04)
Type 2 MI 2.00 (1.52 to 2.62) 2.11 (1.37 to 3.25) 2.03 (1.40 to 2.95)
Type I MI and ischemic stroke 0.91 (0.61 to 1.35) 0.69 (0.41 to 1.16) 1.29 (0.75 to 2.22)
N (limited to those on ART including atazanavir) 5671
Type 1 MI 0.68 (0.43 to 1.09) ‡ ‡
Type 2 MI 0.56 (0.33 to 1.00)
Type I MI and ischemic stroke 0.64 (0.41 to 0.99)
*Analyses adjusted for time-varying viral load and CD4 count, and baseline age, sex, race/ethnicity, HIV transmission risk factor, smoking status, HCV status, diabetes, treated
hypertension, statin use, kidney function (estimated GFR ,30, 30–60, $60), calendar time, and site. Analyses stratified by HCV not adjusted for HCV.
†Note that ART use and atazanavir user are time-varying.
‡Atazanavir analyses not stratified because of small outcome numbers.
GFR, glomerular filtration rate.
stress measured by lipoprotein-associated phospholipase A2
and oxidized low-density lipoprotein was reduced in those on
atazanavir and was correlated with elevated bilirubin levels.41
One of the more compelling studies (AIDS Clinical Trials
Group 5260s) was a trial of ART-naive individuals random-
ized to atazanavir vs. darunavir vs. raltegravir-based regi-
mens. Those on atazanavir had slower carotid intima media
thickness progression than those on darunavir, and in some
analyses, raltegravir. This was associated in part with
bilirubin levels .0.6 mg/dL,21 although bilirubin levels
may also serve as a marker of good ART adherence for
those on atazanavir.42 A recent large study conducted in the
Veterans Affairs (VA) Health Care System suggested that
higher bilirubin levels are associated with decreased cardio-
vascular events such as heart failure and ischemic stroke
among PLWH, although associations with MI were not
statistically significant and that study did not distinguish MI
type.22 Another large study from the VA was conducted in
9500 PLWH.43 A study strength was that it examined the
association of atazanavir with MI and stroke rather than
intermediate outcomes. However, MI and stroke were not
adjudicated, raising concerns about accuracy, and surpris-
ingly, there were higher rates of strokes than MI, raising
questions about MI capture completeness. The VA study
reported a lower incidence of MI and stroke among PLWH on
atazanavir compared with other regimens; however, because
this study was unable to distinguish T1MI from T2MI, it is
not clear whether the findings were similar to ours.
We hypothesized that among PLWH on atazanavir,
higher bilirubin levels would be associated with reduced MI
risk, particularly T1MI. Instead, we found that higher
bilirubin levels were associated with reduced risk of both
types of MI, reaching statistical significance for T2MI risk or
risk of the combined outcome of T1MI and ischemic stroke.
Interestingly, this is in direct contrast to individuals on ART
that did not include atazanavir, in whom higher bilirubin
levels were significantly associated with increased T2MI risk.
These findings are intriguing and suggest that the impact of
bilirubin levels on cardiovascular disease in PLWH may
differ compared with the general population. The difference
in overall findings among those with and without HCV, and
in particular, the protective association of elevated bilirubin
levels among those on atazanavir, where presumably many of
the higher bilirubin levels are due to atazanavir rather than
illness, highlights the diverse causes of elevated bilirubin
levels among PLWH. We suspect that bilirubin elevations due
to benign causes such as atazanavir may be protective, similar
to the protective associations seen with Gilbert syndrome in
the general population. However, other factors such as liver
disease including related to HIV disease itself, viral hepatitis,
and hazardous alcohol use may all contribute to bilirubin
elevation and may not necessarily have protective associa-
tions with either T1MI or T2MI.
We considered whether associations between atazanavir,
bilirubin, and T2MI were due to channeling bias. There is
always a concern about medication channeling, where the
healthier participants are selectively prescribed a particular
pharmacotherapy (eg, atazanavir). However, we suspect that if
the protective association between bilirubin and T2MI among
bilirubin levels were associated with increased risk for 
women only (4.58; 95% CI: 2.06 to 10.1); P value for 
bilirubin · sex interaction term, 0.02.
Findings were also similar but not significant in 
analyses among the subset of 4963 with indirect bilirubin 
values (data not shown).
DISCUSSION
In a large cohort of PLWH with carefully adjudicated 
cardiovascular outcomes, we found that overall, mildly 
elevated levels of total bilirubin (,2.1 mg/dL) were associ-
ated with increased risk of T2MI, particularly among those 
without HCV. Interestingly, among those on ART and 
including all bilirubin values, bilirubin levels were not 
associated with increased T2MI among those currently taking 
atazanavir; in fact, the opposite was the case. In the subset of 
individuals currently on atazanavir, elevated bilirubin levels 
were associated with reduced T2MI risk. Among those 
currently on atazanavir, elevated bilirubin levels were also 
associated with reduced risk of the combined outcome of 
T1MI and ischemic stroke. Mildly elevated bilirubin levels 
(,2.1 mg/dL) had a HR for the association with T1MI that 
was ,1 consistent with protective findings seen in the general 
population; however, this association was not significant. To 
the best of our knowledge, these analyses are one of the 
largest to date evaluating the relationship between bilirubin 
and cardiovascular outcomes among PLWH and the first to do 
so distinguishing T1MI and T2MI.
PLWH with T2MI have previously been shown to have 
more severe HIV disease on average than those with T1MI.31 
Elevated bilirubin in this setting possibly represents the 
greater burden of underlying comorbidity. However, we 
adjusted for HIV disease severity as measured by the time-
varying CD4 count and VL and still found higher bilirubin 
levels were associated with T2MI. We hypothesized that liver 
disease might be a driver of this association; however, the 
association between higher bilirubin and T2MI was particu-
larly notable in those without HCV. Heavy alcohol use and 
alcohol-related liver injury may also be a potential confound-
ing factor, but our findings remained consistent in analyses 
that eliminated those with higher baseline FIB-4 values or 
with more elevated bilirubin levels, who likely comprise most 
patients with alcoholic hepatitis. We were concerned that 
higher bilirubin levels and T2MI may be surrogates for the 
same thing, such as sepsis that caused widespread organ 
ischemia; therefore, all analyses excluded bilirubin levels 
#30 days before the MI to minimize this.
These findings add to the limited literature on bilirubin, 
atazanavir, and cardiovascular disease outcomes in PLWH. A 
cross-sectional case–control study examining carotid intimal 
media thickness found little difference by the bilirubin level, 
but the small sample size (N = 78) limited the conclusions 
that could be drawn.39 A study compared those on atazanavir 
(N = 11) vs. those not on atazanavir (N = 51) and found that 
both atazanavir use and higher baseline total serum bilirubin 
levels were associated with slower mean carotid intima media 
thickness progression.40 Another study of 145 PLWH on 
atazanavir vs. efavirenz-based regimens found oxidative
unconjugated bilirubin levels available; it was a small subset
and no associations were significant. In addition, we did not
limit bilirubin levels to fasting values; associations may be
stronger in studies using fasting bilirubin levels10 because
fasting may impact bilirubin levels.47 Our study is observa-
tional, so causality cannot be inferred. This limitation has also
been noted in general population studies regarding whether
relationships between bilirubin levels and cardiovascular
disease may be causal or due to confounding and reverse
causality.10,48 We stratified overall results by HCV status to
better understand the influence of liver disease, but owing to
low numbers, we were unable to stratify by hepatitis B.
More research seems warranted with carefully adjudi-
cated T1M1 vs. T2MI to better understand the mechanism of
the associations between bilirubin and T2MI, the complicated
relationships between bilirubin and cardiovascular outcomes in
general, and whether there is a protective effect of mildly
elevated bilirubin levels not due to liver disease and the role of
specific antiretroviral medications, potentially done with
unconjugated bilirubin levels rather than total bilirubin. Differ-
ences in associations between those with and without HCV and
receiving or not receiving atazanavir suggest the need for
a nuanced approach to evaluating bilirubin that considers
causes of elevated levels among PLWH. In addition, the larger
risk of T2MI associated with a 2-fold increase in bilirubin
among women than men raises questions regarding reasons for
differences between men and women worthy of future study.
Conclusions
In this large cohort, the HR for the association of higher
bilirubin with T1MI was ,1, consistent with general popula-
tion studies, but not statistically significant. If the antioxidant
effect of bilirubin reduces cardiovascular risk among PLWH,
the impact may be small and difficult to detect even with large
samples. Higher bilirubin levels were associated with increased
T2MI risk, particularly among those without HCV, raising
questions about potential mechanisms. By contrast, among
patients on atazanavir, higher bilirubin levels were associated
with lower risk of T2MI. Among those on atazanavir, higher
bilirubin levels were associated with lower risk of the
combined outcome of T1MI and ischemic stroke. These
findings demonstrate differences in impact of elevated bilirubin
levels due to diverse causes on outcomes among PLWH and
highlight the importance of carefully validated outcomes
including MI types and looking at individual outcomes rather
than composite outcomes where relationships differ.
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